Home > Insider Trading > Filing (0000950170-23-073585)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1450414	Western Standard Partners Lp	5900 Wilshire Boulevard, Suite 650 Los Angeles CA 90036	No	No	No	No
1517666	Western Standard Llc	5900 Wilshire Boulevard, Suite 650 Los Angeles CA 90036	No	No	No	No
1517667	Eric Andersen	5900 Wilshire Boulevard, Suite 650 Los Angeles CA 90036	No	No	No	No
1544857	Western Standard Partners Qp, L.p.	5900 Wilshire Boulevard, Suite 650 Los Angeles CA 90036	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-12-26	48,693	$13.15	533,151	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2023-12-28	857	$13.35	534,008	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.12 to $13.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The shares are directly held by WSP QP. The general partner of the Funds is Western Standard. The managing member of Western Standard and the portfolio manager to the Funds is Mr. Andersen. Each of Western Standard and Mr. Andersen disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.34 to $13.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.